1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited

JAGSNPHARM.NS
Jagsonpal Pharmaceuticals LimitedIN flagNational Stock Exchange of India
232.77
INR
+0.88
- -
15.32BMarket Cap
Jagsonpal Pharmaceuticals Limited
JAGSNPHARM.NS
(National Stock Exchange of India)

Recent

price

232.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
24.58
26.95
25.42
21.98
21.09
21.91
21.97
19.32
25.47
24.21
28.69
33.22
36.14
31.56
40.09
42.67
42.55
Revenue per Share
1.1
1.14
0.28
0.32
0.18
0.5
1.81
-1.76
1.1
1.2
2.6
2.88
4.08
3.4
8.26
6.4
6.38
Basic EPS, GAAP
-0.31
1.08
1.84
1.15
0.66
1.38
-0.89
-0.24
4.72
1.81
4.31
0.9
7.07
5.28
8.17
6.93
- -
Free Cash Flow per Basic Share
0.2
0.2
0.2
0.2
0.04
0.04
0.04
0.04
0.1
0.2
0.4
1.6
- -
1.98
1.97
2.47
- -
Dividend per Share
6.18
6.78
6.8
6.86
6.96
7.38
9.11
7.3
8.28
9.28
10.95
12.59
16.43
17.76
1.98
1.99
1.98
Book Value per Share
14.18
15.03
15.02
15.06
14.57
15.01
16.78
14.65
15.63
16.59
19.06
20.27
24.26
28.34
23.03
29.45
29.36
Tangible Book Value per Share
65
65
65
65
65
65
65
65
65
65
65
65
65
66
67
67
68
Basic Weighted Avg Shares
1,610
1,765
1,665
1,439
1,382
1,435
1,439
1,265
1,668
1,586
1,879
2,176
2,367
2,087
2,687
2,872
2,872
Sales/Revenue/Turnover
7.66
7.98
4.41
5.5
4.43
6.49
2.86
-8.94
5.07
4.67
10
11.28
14.5
10.35
15.98
16.93
16.93
Operating Margin (%)
22
25
27
28
27
31
20
11
10
11
11
15
12
17
81
94
94
Depreciation Expense
72
75
18
21
12
33
119
-116
72
79
171
189
267
225
554
431
431
Net Income, GAAP
22.53
26.1
27.74
16.22
29.95
20.15
17.59
- -
19.85
16.4
22.01
29.23
23.23
24.79
20.75
25.1
25.1
Effective Tax Rate (%)
4.46
4.22
1.1
1.47
0.85
2.27
8.25
-9.13
4.33
4.96
9.08
8.67
11.29
10.76
20.6
15
15
Profit Margin (%)
357
376
364
377
406
436
807
660
694
617
810
821
1,370
1,777
1,353
1,148
1,148
Working Capital
3
3
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
52
76
76
66
66
LT Debt
929
985
984
986
954
984
1,099
980
1,045
1,110
1,249
1,328
1,589
1,874
2,400
2,762
2,762
Total Equity
8.33
8.16
4
4.98
3.18
5.47
2.61
- -
5.92
5.09
11.18
12.59
17.29
9.04
15.31
13.64
13.66
Return on Invested Capital (%)
15.46
10.05
2.33
8.35
4.9
8.54
18.01
- -
13.27
13.08
23.88
23.66
27.47
19.21
75.4
198.98
198.98
Return on Capital (%)
18.57
17.56
4.12
4.74
2.59
6.93
21.97
-21.49
14.14
13.69
25.75
24.46
28.11
19.96
84.72
323.04
323.04
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
16
- -
16
LT Borrowings
- -
- -
- -
LT Finance Leases
72
- -
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
- -
67
Market Capitalization
14,747
12,862
12,423

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,018
- -
1,431
Cash, Cash Equivalents & STI
1,593
- -
1,062
Accounts Receivable, Net
226
- -
172
Inventories
158
- -
146
Total Current Liabilities
333
- -
283
Payables & Accruals
- -
- -
- -
ST Debt
16
- -
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.33%
17.41%
15.1%
Free Cash Flow
-159.38%
125.65%
-14.79%
Net Income, GAAP
19.12%
32.12%
-22.18%
Sales/Revenue/Turnover
8.2%
9.68%
6.89%
Total Cash Common Dividend
- -
- -
25.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
602
578
472
435
2,087
2025
614
747
740
586
2,687
2026
756
745
729
642
2,872

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.14
1.14
0.6
- -
3.4
2025
0.78
1.72
4.74
0.98
8.26
2026
1.6
1.88
1.67
1.25
6.4

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.98
2025
- -
- -
- -
- -
1.97
2026
- -
- -
- -
- -
2.47
Similar Companies
Herborium Group, Inc. (HBRM)
Mountain High Acquisitions Corp. (MYHI)
Discover Wellness Solutions Inc. (WLNSF)
BNC Korea Co., Ltd. (256840.KQ)
Lumiera Health Inc. (NHPHF)
Elite Pharmaceuticals, Inc. (ELTP)
Business
Jagsonpal Pharmaceuticals Limited manufactures, sells and trades pharmaceutical formulations and active pharmaceutical ingredients in India and internationally. The company offers products in gynaecology, orthopaedics, dermatology, paediatrics, antibiotics, allergy management, immunity and cell protection, OTC products; formulations include tablets, softgels, injections, capsules and syrups such as Maintane, Metabolin, Parvon, Rowezy and Queezy; it maintains 17 brands among the top five in their molecule categories, with top five brands contributing about 47% and top seven about 67% of revenues. Founded in 1978 and headquartered in New Delhi, India, Jagsonpal operates through a sales team of over 900 personnel with a pan-India presence and serves healthcare professionals and government institutions. In 2024, the company acquired the India and Bhutan businesses of Yash Pharma, integrating 33 established brands in dermatology and paediatrics to expand into a market segment valued at INR 20,000 crore and enhance therapeutic reach. It recently appointed a chief operating officer and chief financial officer, reported half-year revenue of INR 150.1 million and PAT of INR 234 million for FY26 with 10.2% and 39.2% year-over-year growth respectively, and sustains strong profit growth of 38.2% CAGR over five years while remaining nearly debt-free.